AUTHOR INDEX

Acherman, Y.I.Z., 51
Aglione, S., 427
Alexander, H.R., 136
Allegra, C., 222
Altomonte, M., 471

Baas, P., 62
Bajetta, E., 427
Bernard-Marty, C., 427
Botstein, D., 280
Bouvet, M., 341
Britton, M., 18
Buzzoni, R., 427

Canil, C.M., 286
Carbone, M., 2
Cassileth, B.R., 585
Cattell, E., 513
Classen, R., 308
Cohen, I., 563
Cook, M.G., 370
Curley, S.A., 168
Curt, G.A., 529

Del Vecchio, M., 427
Dizon, D.S., 126
Douglas, J.G., 518

Eggermont, A.M.M., 382
Elizabeth, M., 213
Ellis, L.M., 168
Ensminger, W.D., 119
Erasmus, J.J., 26

Fizazi, K., 77
Flaherty, L.E., 446
Foletto, M., 400
Fornage, B.D., 168

Gadgeel, S.M., 446
Gelmann, E.P., 246
Giovannini, M., 192
Girling, D.J., 97
Gonzalez-Angulo, A.M., 462
Gonzalez-Moreno, S., 51
Gore, M., 382
Gore, M.E., 456
Gutman, S., 294

Hammond, H., 213
Hayes, D.F., 231
Herba, M.J., 152

Izadpanah, A., 336

John, W.J., 77

Keilholz, U., 456
Kelly, C., 513
Kemeny, N., 126
Khayat, D., 427
Kindler, H.L., 1, 70, 82
Krag, D.N., 274
Kratzke, R.A., 2

Lake, R.A., 82
LI, Y., 413
Lise, M., 400
Liu, M.C., 246
Lobban, D., 97
Lutzky, J., 462

Machiels, J-P., 494
Maio, M., 306, 471
Malik, U., 196
Mansky, P.J., 589
Marcahnd, M., 494
Marchettini, P., 51
Margolin, K., 518
Marom, E.M., 26
Mastrangelo, M.J., 305, 306
McClay, E.F., 306, 389, 413
Middleton, M.R., 513
Minev, B.R., 479
Mocellin, S., 400
Mohiuddin, M., 196
Monaco, G.P., 601
Mozzillo, N., 328
Muers, M.F., 97

Nagi, C., 336
Nahim, R.L., 552
Nova, P., 427
Nowak, A.K., 82

O'Grady, T.C., 336
Oh, W.K., 575
Ortega-Perez, G., 51
Orzano, J.A., 462

Parikh, A.A., 168
Pass, H.I., 26
Patz, E.F. Jr., 26
Pilatti, P., 400
Pollack, J.R., 280
Proebstle, T.M., 353

Qian, W., 97

Ravikumar, T.S., 183
Richardson, M.A., 531
Rixe, O., 427
Roach, M. III, 264
Robinson, B.W.S., 82
Rosenwald, A., 258
Rossi, C.R., 400
Ruiter, D.J., 370

Sampson, W., 595
Sargent, D., 222
Sasson, A.R., 107
Sato, T., 105, 160
Schadendorf, D., 503
Schilsky, R.L., 211
Schoengen, A., 353
Shen, J., 341
Sh;auurzer-Voit, M., 353
Sigurdson, E.R., 107
Small, E.J., 264, 575
Smith, G., 601
Sotsky, T.K., 183
Spatz, A., 370
Staudt, L.M., 258
Steele, J.P.C., 36
Sterry, W., 353
Straus, S.E., 531
Stuart, O.A., 51
Sugarbaker, D.J., 41
Sugarbaker, P.H., 51
Sullivan, K.L., 145

Tagliaferri, M., 563
Tallibert, S., 427
Tannock, I.F., 286
Taube, S.E., 211, 213
Testa, J.R., 2
Testori, A., 328
Thirlwell, M.P., 152
Thompson, J.A., 361
Thor, A.D., 231
Tripathy, D., 563

Ulrich, J., 353

van Baren, N., 494
van de Rijn, M., 280
van den Oord, J.J., 370
van Meerbeeck, .P., 70
Vitali, M., 427
Vogelzang, N.J., 1, 77
Voigt, H., 308
Voit, C., 353

Wallace, A.M., 341
Weaver, D.L., 274
Weber, L., 353
Weinreich, D.M., 136
White, J.D., 546

Yarbro, J.W., 305
Yoo, D., 51

Zellos, L.S., 41

AUTHOR INDEX

Acherman, Y.I.Z., 51
Aglione, S., 427
Alexander, H.R., 136
Allegra, C., 222
Altomonte, M., 471

Baas, P., 62
Bajetta, E., 427
Bernard-Marty, C., 427
Botstein, D., 280
Bouvet, M., 341
Britton, M., 18
Buzzoni, R., 427

Canil, C.M., 286
Carbone, M., 2
Cassileth, B.R., 585
Cattell, E., 513
Classen, R., 308
Cohen, I., 563
Cook, M.G., 370
Curley, S.A., 168
Curt, G.A., 529

Del Vecchio, M., 427
Dizon, D.S., 126
Douglas, J.G., 518

Eggermont, A.M.M., 382
Elizabeth, M., 213
Ellis, L.M., 168
Ensminger, W.D., 119
Erasmus, J.J., 26

Fizazi, K., 77
Flaherty, L.E., 446
Foletto, M., 400
Fornage, B.D., 168

Gadgeel, S.M., 446
Gelmann, E.P., 246
Giovannini, M., 192
Girling, D.J., 97
Gonzalez-Angulo, A.M., 462
Gonzalez-Moreno, S., 51
Gore, M., 382
Gore, M.E., 456
Gutman, S., 294

Hammond, H., 213
Hayes, D.F., 231
Herba, M.J., 152

Izadpanah, A., 336

John, W.J., 77

Keilholz, U., 456
Kelly, C., 513
Kemeny, N., 126
Khayat, D., 427
Kindler, H.L., 1, 70, 82
Krag, D.N., 274
Kratzke, R.A., 2

Lake, R.A., 82
LI, Y., 413
Lise, M., 400
Liu, M.C., 246
Lobban, D., 97
Lutzky, J., 462

Machiels, J-P., 494
Maio, M., 306, 471
Malik, U., 196
Mansky, P.J., 589
Marcahnd, M., 494
Marchettini, P., 51
Margolin, K., 518
Marom, E.M., 26
Mastrangelo, M.J., 305, 306
McClay, E.F., 306, 389, 413
Middleton, M.R., 513
Minev, B.R., 479
Mocellin, S., 400
Mohiuddin, M., 196
Monaco, G.P., 601
Mozzillo, N., 328
Muers, M.F., 97

Nagi, C., 336
Nahim, R.L., 552
Nova, P., 427
Nowak, A.K., 82

O'Grady, T.C., 336
Oh, W.K., 575
Ortega-Perez, G., 51
Orzano, J.A., 462

Parikh, A.A., 168
Pass, H.I., 26
Patz, E.F. Jr., 26
Pilatti, P., 400
Pollack, J.R., 280
Proebstle, T.M., 353

Qian, W., 97

Ravikumar, T.S., 183
Richardson, M.A., 531
Rixe, O., 427
Roach, M. III, 264
Robinson, B.W.S., 82
Rosenwald, A., 258
Rossi, C.R., 400
Ruiter, D.J., 370

Sampson, W., 595
Sargent, D., 222
Sasson, A.R., 107
Sato, T., 105, 160
Schadendorf, D., 503
Schilsky, R.L., 211
Schoengen, A., 353
Shen, J., 341
Sh;auurzer-Voit, M., 353
Sigurdson, E.R., 107
Small, E.J., 264, 575
Smith, G., 601
Sotsky, T.K., 183
Spatz, A., 370
Staudt, L.M., 258
Steele, J.P.C., 36
Sterry, W., 353
Straus, S.E., 531
Stuart, O.A., 51
Sugarbaker, D.J., 41
Sugarbaker, P.H., 51
Sullivan, K.L., 145

Tagliaferri, M., 563
Tallibert, S., 427
Tannock, I.F., 286
Taube, S.E., 211, 213
Testa, J.R., 2
Testori, A., 328
Thirlwell, M.P., 152
Thompson, J.A., 361
Thor, A.D., 231
Tripathy, D., 563

Ulrich, J., 353

van Baren, N., 494
van de Rijn, M., 280
van den Oord, J.J., 370
van Meerbeeck, .P., 70
Vitali, M., 427
Vogelzang, N.J., 1, 77
Voigt, H., 308
Voit, C., 353

Wallace, A.M., 341
Weaver, D.L., 274
Weber, L., 353
Weinreich, D.M., 136
White, J.D., 546

Yarbro, J.W., 305
Yoo, D., 51

Zellos, L.S., 41

SUBJECT INDEX

Ab1, 473
Ab2β, 473
Ab3, 473-474
ABCD rule, 309, 310, 314
Acupuncture, 533-534
  in prostate cancer, 577
Adaptive immunotherapy, locoregional, 163-164
Adenocarcinoma, microscopic profiles of, 42
Adenovirus, replication-deficient, 205-206
Adjuvant systemic therapy, 231
American Society for Therapeutic Radiation Oncology Consensus Panel, 265-266
Amifostine, in metastatic melanoma, 429-430
Amosite, 4, 24
Amphibole fiber, 4
Amsacrine, for mesothelioma, 66
Analyte-specific reagents, FDA definition of, 299
Anecdotes, informed consent and, 602-603
Angiogenesis, tumor, 375
Anthophyllite, 4
Anti-idiotype network theory, 462-463
Anti-idiotype vaccine, 464-465
  in melanoma, 465-467
Anti-idiotypic antibody, mechanism of action of, 472
Antiangiogenic therapy, in metastatic melanoma, 440
Antibody, as assay reagent, 233
Antibody-based fusion protein, mechanism of action of, 472
Antibody-dependent cell-mediated cytotoxicity, 472
Antigen, melanoma, 480-481
Antigen-presenting cell, 86
Antioxidants, with chemotherapy and radiotherapy, 542
Antitumor immune response, 83
Arteriovenous shunting, in hepatic arterial therapy, 122-123
Asbestos
  experimental models for, 7
  exposure to, 4, 6-9
  fiber types in, 22-23
  human mesothelioma and, 9-10
  malignant mesothelioma and, 3-5
  occupational exposure to, 19-20
  pathogenic mechanisms of, 5
Asbestosis, 3-4
  mesothelioma frequency *v*, 8
Assay, for tumor markers, 215-217
Ayurveda, 537
Azacytidine, in combination chemotherapy, 66-67
Aziridinylbenzoquinone, for mesothelioma, 66

BAGE gene, 480-481
Baicalein, 535
BEC2, 466
Best case series
  definition of, 552-553
  studies for, 554-557
Best case series program, 549
Betulinic acid, 417
Bevacizumab, in mesothelioma, 91-92
Biochemotherapy
  in adjuvant setting, 453
  in melanoma, 457
  in metastatic melanoma, 436-438, 448-453
  outpatient regimens of, 451-452
  phase III trials of, 452-453
  sequence of, 451
Biological response modifier, regional treatment with, 160-163
Bispecific antibody, mechanism of action of, 472
Black dot, 314
Black spot, 4
Bladder cancer, p53 and, 251
Bleomycin
  in combination chemotherapy, for mesothelioma, 66-67
  in polychemotherapy, for metastatic melanoma, 432
Bleomycin, vincristine, lomustine, dacarbazine regimen, in melanoma, 422
Blue-white veil, 314
BOLD regimen, 433
Border, irregularity of, 318, 319
Botanicals, drug interactions with, 542
Brachytherapy, intraoperative, 47
Brain metastasis
  chemoimmunotherapy in, 516
  chemotherapy in, 515, 521-522
  radiosurgery in, 514, 519
  stereotactic radiosurgery in, 520-521
  surgical management of, 513-514, 519
  whole brain irradiation in, 514-515
Breadloafing, 337
Breast cancer
  Chinese medicine in, 571-572
  microarray analysis in, 283
  micrometastasis in, 276-277
  neoadjuvant therapy in, Chinese medicine as, 572
  P53 and, 251-252
  prevention of, Chinese medicine for, 568-569
  sentinel lymph node status in, 277
  traditional Chinese medicine in, 563-568
  tumor markers in, 213
  Western medicine plus Chinese medicine in, 569-571
Brigham Dana-Farber Cancer Institute staging system, revised, 43
Bryostatin-1, 417
Butchart staging system, 43

c-erbB-2
  adjuvant tamoxifen therapy and, 236
  alkylating agent resistance and, 237-238
  analysis methods for, 232-234
  anthracycline-based therapy and, 238-239
  as chemotherapy predictive factor, 239
  endocrine therapy response and, 237
  extracellular domain of, 231-232
  as marker, 232
  marker development of, steps in, 241
  potential uses of, as tumor marker, 234

c-erbB-2 (*Continued*)
as predictive factor, 235-239
as prognostic factor, 234-235
taxanes and, 239
trastuzumab and, 239-240
c-erbB-2 gene, 232
C-*fos*, 15
C-*jun*, 15
C-*kit*, 225
Caelyx, for mesothelioma, 63
Camera dermatoscope, 316
Cancer
complementary and alternative medicine in, 531-532
data analysis in, 281
DNA microarray in, 280
gene expression patterns in, 281
psychosocial support in, 596-598
specimen selection in, for molecular characterization, 280
stress and, 314
tumor heterogeneity in, 280-281
Cancer Advisory Panel, on Complementary and Alternative Medicine, 549
Cancer and Leukemia Group B prognostic scoring system, 38
Cancer germ-line gene, 494
Cancer Patient Educators Network, 532
Cancer personality, 596
Cancer screening
definition of, 286
tumor markers and, 286-287
CancerVax vaccine, 482
Carboplatin
in combination chemotherapy, for mesothelioma, 74-75
for mesothelioma, 63
in metastatic melanoma, 429-430
Carboplatin, cisplatin regimen, in melanoma, 421
Carboplatin, dacarbazine, tamoxifen regimen, in melanoma, 421
Carcinoembryonic antigen, rising, 288
Carmustine
in melanoma, 428
in metastatic melanoma, 430
in polychemotherapy, for metastatic melanoma, 432
Carmustine, dacarbazine, cisplatin, tamoxifen regimen, in melanoma, 417-420
CB11, 233
CCI-779, 439
CD117, 225
CD40, 375
CD59, 472-473
CD8 effector response, 86
Cell microarray, 284
Central processing unit, 316
Chemoimmunotherapy
in brain metastasis, 516
in malignant mesothelioma, 90-91
regional, 162
Chemoradiation
adjuvant, 45-47
extrapleural pneumonectomy and, 45-47
Chemotherapy
adjuvant, hepatic resection and, 129-131
c-erbB-2 and, 237-239
Chemotherapy (*Continued*)
combination, *see* Polychemotherapy
external-beam radiation therapy and, 199-200
hepatic arterial, *see* Hepatic arterial infusional chemotherapy
history of, in mesothelioma, 77-78
interferon and, in melanoma, 448-449
interleukin and, in melanoma, 449
in malignant pleural mesothelioma, 62-63
in melanoma, 396-397
in multimodality therapy, 47-48
neoadjuvant, hepatic resection and, 131
single-agent, 413-417, 427, 446
in stage IV melanoma, 384
in unresectable malignant mesothelioma, 97-98
Chinese Medical Syndrome Classification, 570
Chinese medicine, *see* Traditional Chinese medicine
Chlorozotocin, in melanoma, 428
Chromogenic in situ hybridization, 232, 233
Chromosome 22, in mesothelioma, 14
Chronic lymphocytic leukemia, 260-262
molecular diagnosis of, 261
Chrysotile, 22, 24
Chymostrypsin, in cancer therapy, 536
CI-980, 416
Cisplatin, 404, 436, 437, 450
in combination chemotherapy, 66-67, 73-74, 78-79
in isolated limb perfusion, 401
for mesothelioma, 63
in metastatic melanoma, 429-430
in polychemotherapy, for metastatic melanoma, 432
Cisplatin, carboplatin regimen, in melanoma, 421
Cisplatin, dacarbazine, carmustine, tamoxifen regimen, in melanoma, 417-420
Cisplatin, dacarbazine, fotemustine, tamoxifen regimen, in melanoma, 420
Cisplatin, dacarbazinea, tamoxifen regimen, in melanoma, 421
Cisplatin, etoposide regimen, in melanoma, 422
Cisplatin, tamoxifen regimen, in melanoma, 396-397, 420
Cisplatin, tirapazamine regimen, in melanoma, 422
Clear cell artifact, 338
Cochrane Collaboration, 538
Collin's formula, 120-121
Colon cancer
early relapse treatment in, 288-289
microsatellite instability in, 214, 227
p53 and, 250-251
Colorectal cancer
metastatic, hepatic resection for, 107-108
recurrence patterns in, 169
recurrent hepatic metastases of, 114-115
Combination chemotherapy, *see* Polychemotherapy
Compactness index, 318
Complement-dependent cytotoxicity, 472
Complementary and alternative medicine
in cancer, 531-532
cancer centers investigating, 549
in cancer patients, 547
cancer research of, 546-547
definition of, 531, 546, 595

Complementary and alternative medicine (*Continued*)
future of, in cancer research, 550
history of, at National Cancer Institute, 550
information sources about, 537-538
informed consent case studies in, 604-605
informed consent in, 601-602
informed consent principle in, 603-604
invalid consents in, 605-606
at life's end, 541-542
mandate for, 538-540
National Cancer Institute research programs of, 547-550
nondisclosure of, 533
oncology informed consent in, 605
PDQ evidence levels for, 538
research challenges in, 537
topics of, in Grant Portfolio, 550
use of, 531
Complementary and alternative medicine cancer information program, 549-550
Complementary and alternative therapy, in prostate cancer, 575
Computed tomography
following chemoembolization, 146
following radioembolization, 155, 156, 157
following radiofrequency ablation, 173-175
in hepatic metastasis evaluation, 111-112
in malignant pleural mesothelioma, 26-28
in peritoneal mesothelioma, 54, 55
in peritoneal mesothelioma diagnosis, 53
Computed tomography arterial portography, in hepatic metastasis evaluation, 112
Computer-aided topodermatographic image analysis, 319-320
Consent, informed
anecdotes and, 602-603
case studies of, 604-605
in complementary and alternative medicine, 601-602, 603-604
invalid, 605-606
liability and, 606
CpG DNA, 498
Crocidolite, 4, 24
Cryoablation, 185
Cryosurgical ablation, 179, 180-181
Cryotherapy
complications of, 189-190
contraindications for, 184
current indications for, 183-184
history of, 183
outcomes following, 186-189
physiology and, 185-186
recurrence sites following, 189
technique for, 184-185
Crysotile, 4
Cutpoint system, 233
Cyclophosphamide
in combination chemotherapy, 66-67
for mesothelioma, 66
Cytarabine, in metastatic melanoma, 429-430
Cytokine(s), 438
in malignant mesothelioma, 85
in metastatic melanoma, 435, 436
Cytokine gene transfer
in vivo, 506-508
into allogeneic tumor cells, 505-506
into autologous tumor cells, 504-505
into mixed tumor cells, 506
into xenogeneic tumor cell, 506
targeting signal transduction, 508-509
Cytosine deaminase gene, 205
Cytotoxicity
antibody-dependent cell-mediated, 472
complement-dependent, 472

Dacarbazine, 404, 436, 437, 449, 450
in melanoma, 446
in metastatic melanoma, 413-414, 427-428
in polychemotherapy, 432
temozolomide *v*, 428-429
Dacarbazine, bleomycin, vincristine, lomustine regimen, in melanoma, 422
Dacarbazine, carboplatin, tamoxifen regimen, in melanoma, 421
Dacarbazine, carmustine, cisplatin, tamoxifen regimen, in melanoma, 417-420
Dacarbazine, cisplatin, tamoxifen regimen, in melanoma, 421
Dacarbazine, fotemustine, cisplatin, tamoxifen regimen, in melanoma, 420
Dacarbazine, Genasense regimen, in melanoma, 423
Dacarbazine, vindesine regimen, in melanoma, 421-422
Dartmouth regimen, 433, 450
in melanoma, 417
Dendritic cell, 86, 486-487
Dermatoscope, 312
camera, 316
Dermatoscopic score index, 315
Dermatoscopy, 311-312
computer-based, 316-319
for lesion analysis, 318
naked eye inspection *v*, 312
Dermoscopy, 312
Detorubicin, for mesothelioma, 63
DETOX, 482
Dexamethasone, hepatic toxicity and, 131-132
Di Bella multitherapy, 536
Dibromodulcitol, in polychemotherapy, for metastatic melanoma, 432
Dichotomized system, 233
Diffuse large B-cell lymphoma, 259-260
subtypes of, 260
Diffuse malignant pleural mesothelioma
chemotherapy in, 45
clinical presentation in, 41
diagnosis of, 41
incidence of, 41
microscopic profiles of, 42
multimodality therapy in, 45-48
novel therapies in, 48-49
radiation therapy in, 43-45
staging of, 42-43
surgery in, 44-45
Digital dermatoscopy, for lesion analysis, 318
Digital standard dermatoscopic point score, 317

Digitization, definition of, 310
Discrimination, definition of, 311
Division of Clinical Laboratory Devices, 294, 298
DNA innoculation, 509-510
DNA microarray
  in cancer, 280
  data analysis in, 281
  gene expression patterns in, 281
  gene prioritization and, 282
  gene validation and, 282-283
  smaller, 283-284
  specimen selection for, 280
  tumor heterogeneity and, 280-281
Docetaxel
  in melanoma, 416
  in metastatic melanoma, 430-431
Dolastatin-10, 416-417
Doxorubicin
  in combination chemotherapy, 66-67
  for mesothelioma, 63
Dye, blue, in lymphatic mapping, 343

E1B 55K, 205
E7070, 439
Edatrexate, for mesothelioma, 64-65
Effectiveness, FDA definition of, 295
Enzyme(s), as cancer therapy, 535-536
Enzyme-linked immune spot, 497, 498
Enzyme-linked immunoassay, 232
Epidermal growth factor, in mesothelioma, 92
Epiluminescence microscopy, 311-312
Epirubicin
  in combination chemotherapy, 66-67
  for mesothelioma, 63
Epithelial mesothelioma, 56, 57
Erionite, 11-12
Estramustine, in melanoma, 428
Estrogen receptor
  as marker, 232
  as predictive factor, 223
Estrogen receptor assay, in breast cancer, 214
Etoposide
  in combination chemotherapy, 66-67
  for mesothelioma, 66
Etoposide, cisplatin regimen, in melanoma, 422
European Organization for Research and Treatment of Cancer Prognostic Scoring System, 38-39
External-beam radiation therapy
  chemotherapy and, 199-200
  misonidazole and, 200
  prostate-specific antigen and, 266
  trials of, 198
Extrapleural pneumonectomy, 43
  adjuvant chemoradiation and, 45-47

FDA, *see* Food and Drug Administration
Fine-needle aspiration cytology, ultrasound-guided, in melanoma, 357
510(K) review, 295-296
Flap necrosis, 334
Flavopiridol, 439
Floxuridine
  in hepatic arterial infusional therapy, 120-123
  hepatic toxicity of, 131-132
Fluorescent in situ hybridization, 232
  kits for, 233-234
Fluorouracil, 199-200
Food and Drug Administration
  mission of, 299-300
  premarket approval application, 295
Food and Drug Administration submission
  analytical data requirements for, 296-297
  clinical data requirements for, 297-298
  for tumor markers, 296-297
  regulatory resources for, 298
Fotemustine, 521
  in brain metastasis, 515, 521-522
  efficacy of, in metastatic melanoma, 430
  in melanoma, 415-416, 428
Fotemustine, dacarbazine, cisplatin, tamoxifen regimen, in melanoma, 420
Fractal dimension, 318

GAGE gene, 480-481
GAPDH, 261
Gastrointestinal stromal tumor, 225
GD2, 472
GD3, 472
Gemcitabine
  in combination chemotherapy, 73-75
  with enzyme therapy, 536
  future directions for, 75
  in malignant mesothelioma, 70-73
  phase II trials of, 71
  survival following, 72
Genasense, 509
Genasense, dacarbazine regimen, in melanoma, 423
Gene amplification, 232
Gene expression profile, 258-259
Gene gun, 486
Gene therapy, 202
  intralesional, 166
  in malignant mesothelioma, 87-89
Gene transfer
  in vivo, 506-508
  into allogeneic tumor cells, 505-506
  into autologous tumor cells, 504-505
  into mixed tumor cells, 506
  into xenogeneic tumor cells, 506
  targeting signal transduction, 508-509
Genetic immunization, 509-510
Genetics, human mesothelioma and, 11-13
Germ cell tumor, early relapse treatment in, 290
Gibbs-Donnon equilibrium, 186
Ginseng, 534-535
Gleason pattern, 216, 217
Gleevec, 225
Globule, 314
Glycerrhize, 534-535
Gonzalez regimen, 535-536
Granulocyte-macrophage colony-stimulating factor
  liver metastases and, 164-166

Granulocyte-macrophage colony-stimulating factor (*Continued*)
in malignant mesothelioma, 85
in melanoma, 395
Great Britain, mesothelioma mortality in, 23-24
Gruppo Universitario Napoletano 1, 235-239

Head, squamous cell carcinoma of, p53 and, 252-253
Heat shock protein, 89
Hemi-hepatectomy, 113
Hepatic arterial infusion, of biological response modifiers, 161-163
Hepatic arterial infusional chemotherapy
arteriovenous shunting in, 122-123
cost of, 131
delivery mechanism in, 119-120
drug properties essential in, 122
extrahepatic recurrence and, 132
hepatic toxicity and, 131-132
history of, 127
patient selection for, 127
pharmacologic principles in, 120-123
pump placement in, 127-128
randomized trials of, 128-129
rationale for, 126-127
technological solutions for, 124
toxicity of, 132-133
Hepatic artery chemoembolization
clinical outcomes following, 148-150
rationale for, 145-148
Hepatic metastasis
disease-free interval and, 110
distribution of, 112
extrahepatic disease extent in, 108-109, 111-112
hepatic resection contraindications in, 111
hepatic resection margins in, 109
locoregional treatment of, 105-106
long-term results of, and hepatic resection, 107-108
natural history of, 107
negative prognostic factors in, and hepatic resection, 108
number of, and hepatic resection, 110
primary tumor stage and, 109
prognostic factors in, 108-110
recurrent, of colorectal cancer, 114-115
size of, 110
unresectable, 115
Hepatic resection
adjuvant chemotherapy and, 129-131
adjuvant therapy and, 115-116
complications of, 114
morbidity following, 114
mortality following, 114
nomenclature in, 112, 113
operative considerations in, 112-114
preoperative evaluation in, 111-112
prognostic factors in, 108-110
repeat, outcome following, 115
HER2, 232
assay for, 215
assay standardization for, 218
Herbal mixture(s), 534-535
for prostate cancer, 534
Herbal therapy, in prostate cancer, 577-582
Herbs, 534-535
commonly used, for cancer, 565-567
HercepTest, 233
Herpes simplex virus, 203-205
Hierarchical clustering analysis, DNA microarray and, 282
Histamine, in phase III trials, 460
Home brew assay, 298-299
Hormonal therapy, in metastatic melanoma, 431
Hydropneumothorax, 33
Hyperbaric oxygen therapy, 540
Hyperthermia, in multimodality therapy, 48

Idiotype network model, clinical applications of, 464
Ifosfamide
in combination chemotherapy, 66-67
in melanoma, 428
for mesothelioma, 65
Image, definition of, 310
Image resolution, definition of, 310
Immune response, antitumor, 83
Immunization
genetic, 509-510
with recombinant protein, 499
Immuno(bio)therapy
locoregional, for hepatic metastases, 160
rationale for, 160
Immunoembolization, of hepatic metastases, 164-166
Immunogene therapy, 206
Immunogene-based therapy, 504
Immunohistochemistry, 215, 232
Immunomodulatory gene therapy, in malignant mesothelioma, 88
Immunostain, of peritoneal mesothelioma, 57
Immunostimulant, in malignant mesothelioma, 83
Immunotherapy
active, 473-474
in malignant mesothelioma, 82-87
in metastatic melanoma, 435-436, 447-448
passive, 471-473
In vitro diagnostic device, 219
FDA labeling of, 298
Informed consent
case studies in, 604-605
in complementary and alternative medicine, 601-602
invalid, 605-606
principles in, 603-604
Integrative Medicine Service
administration of, 588
inauguration of, 586
inpatient, 586-587
outpatient, 587-588
outreach educational program in, 588
research in, 588
steps for, 586
structure of, 585
Integrin, 374-375
Interferon
chemotherapy and, in melanoma, 448-449

Interferon (*Continued*)
in combination chemotherapy, 66-67
in malignant mesothelioma, 83-84
in melanoma, 392-395, 422
in metastatic melanoma, 429-430, 434, 447-448
phase 3 trials of, 384-386
polychemotherapy and, with interleukin-2, 449-451
Interferon-alpha, 456
in melanoma, 383-384
in metastatic melanoma, 435, 436, 437
Interferon-gamma, 404
Interleukin, chemotherapy and, in melanoma, 449
Interleukin-2, 456-457, 498
in combination chemotherapy, 66-67
in malignant mesothelioma, 83-85
in metastatic melanoma, 435, 436, 437, 447-448
polychemotherapy and, with interferon, 449-451
subcutaneous, in metastatic melanoma, 437
Interleukin-12, 438-439, 498
in malignant mesothelioma, 85
International Germ Cell Consensus Classification for Nonseminomas, 288
International Mesothelioma Interest Group staging system, 43, 44
Investigational Device Exemption, 297
Irinotecan
in combination chemotherapy, 66-67
for mesothelioma, 66
Iscador, 534
ISCAR, 534
Isolated hepatic perfusion, 162-163
clinical results with, 138-141
cytokine concentrations following, 140
with melphalan, 142
in ocular melanoma, 141-143
percutaneous, 141-143
previous trials of, 139
procedure of, 137-138
schematic representation of, 137
treatment parameters during, 138
Isolated limb perfusion, 136-137
in melanoma, 400
technique in, 401-402
toxicity of, 405, 406

Jerne's theory, 473
Johns Hopkins Center for Cancer Complementary Medicine, 540

Kang Lai Te, 571
Kelley-Gonzalez regimen, 549
Kiel classification, 258

Lactate dehydrogenase, 365-366
Laetrile, 536
LAK cell, in malignant mesothelioma, 83
Lesion analysis, 318
Levamisole, in melanoma, 395-396
Liver
anatomical *v* nonanatomical resection of, 113-114
intraoperative ultrasound of, 113-114
Liver (*Continued*)
radiation effects on, 196-197
radiotherapy of, 197-198
segmental anatomy of, 113
segmental *v* wedge resection of, 113-114
surgery of, *see* Hepatic resection
Lobectomy, 113
Lomustine
in melanoma, 428
in metastatic melanoma, 430
Lomustine, bleomycin, vincristine, dacarbazine regimen, in melanoma, 422
LU103793, 417
Lung burden study, in mesothelioma, 20-22
Lung cancer
asbestos and, 3-4
p53 and, 252
Lycopene, in prostate cancer, 576-577
Lymph node, ultrasound B-scan pattern of, 355-356
Lymph node dissection
elective, 342
in melanoma, 342
Lymphatic mapping
clinical trials of, in melanoma, 344
technique of, in melanoma, 347-348
Lymphoscintigraphy, 332
intraoperative, in melanoma, 343-344
preoperative, in melanoma, 345-347

MAGE gene, 480-481, 494
MAGE-3, 499
Magnetic resonance imaging, 320-321
following radiofrequency ablation, 173-175
in hepatic metastasis evaluation, 112
of isolated hepatic perfusion, 142
in malignant pleural mesothelioma, 28-29
Malignant mesothelioma
asbestos and, 3-5
Cancer and Leukemia Group B prognostic scoring system in, 38
chemoimmunotherapy in, 90-91
clinical prognostic factors in, 36-38
diagnostic confirmation in, 36
dying from, probability of, 23
epidermal growth factor in, 92
gemcitabine in, 70-73
gene therapy in, 87-89
genetic alterations in, 12-15
genetics and, 11-12
immunotherapy in, 82-87
local recurrence in, 34
mineral fiber analysis in, 21
palliation in, 98
pathogenesis of, 5
platelet-derived growth factor in, 92
prognosis in, 36
progress in, 1
quality of life in, 98
randomized trials in, 98-99
recurrent, 33
smoking and, 3-4

Malignant mesothelioma (*Continued*)
unresectable, chemotherapy in, 97-98
vaccine for, 89-90
vascular endothelial growth factor in, 91-92
Malignant pleural mesothelioma
chest radiography in, 26
CT in, 26-28
diffuse, international staging system for, 32
MRI in, 28-29
paramediastinal radiation changes in, 31
PET in, 29-30
right-sided diffuse, 31
single-agent chemotherapy in, 62-63
staging of, 31-32
tissue diagnosis of, 30-31
TNM stage classification in, 32
Marker, tumor, *see* Tumor marker(s)
Megestrol, in melanoma, 428
Melanin pigment network, 312, 314
Melanoma
ABCD rule for, 309, 314
adjuvant surgery for, 382-383
adjuvant systemic therapy for, 383-386
adjuvant therapy patient selection in, 389-391
American *v* European perspectives on, 306-307
analyzing view of, 310-311
antiangiogenic therapy in, 440
betulinic acid in, 417
biochemotherapy in, 448-453
bleomycin, vincristine, lomustine, dacarbazine regimen in, 422
bryostatin-1 in, 417
carboplatin in, 429-430
CI-980 in, 416
cisplatin in, 429-430
cisplatin, carboplatin regimen in, 421
cisplatin, etoposide regimen in, 422
cisplatin, tirapazamine regimen in, 422
clinical diagnosis of, 308-309
combination chemotherapy in, *see* Polychemotherapy
dacarbazine in, 413-414
dacarbazine, carboplatin, tamoxifen regimen in, 421
dacarbazine, carmustine, cisplatin, tamoxifen regimen in, 417-420
dacarbazine, cisplatin, tamoxifen regimen in, 421
dacarbazine, fotemustine, cisplatin, tamoxifen regimen in, 420
dacarbazine, Genasense regimen in, 423
dacarbazine, vindesine regimen in, 421-422
Dartmouth regimen in, 417
docetaxel in, 416
dolastatin-10 in, 416-417
EORTC trial in, 457-460
fotemustine in, 415-416
hormonal therapy in, 431
immunotherapy in, 435-436, 447-448
incidence of, 341, 446
increasing incidence of, 361
lesion surveillance in, 309
LU103793 in, 417
lymph node metastasis of, 342
metastasis staging in, 365-366
Melanoma (*Continued*)
micrometastases *v* macrometastases in, 364
micrometastasis in, 275-276
molecular staging in, 374-375
new chemotherapeutic agents in, 439
new staging in, pathologic implications of, 370-371
new staging system in, 275-276
nitrosourea agents in, 415-416
node staging in, 364-365
ocular, isolated hepatic perfusion in, 141-143
paclitaxel, tamoxifen regimen in, 420-421
paclitaxel in, 416
pathologic stage III, 365
pathologically staged, 364
primary ulceration of, 365
proposed stage groupings for, 363
regional node recurrence in, 276
revised American Joint Committee staging system for, 361-368
satellites *v* in-transit metastases in, 364-365
screening studies in, 391-392
seven-point checklist for, 309, 314
single-agent chemotherapy in, 413-417
stage grouping in, 366
stage III, 371-372
stages I and II, 371
staging changes in, 367
superficial spreading, 313
surgical excision of, 328-330
tamoxifen, cisplatin regimen in, 420
temozolomide in, 414-415
thalidomide in, 417
TNM classification of, 362
tumor microstaging in, 362-364
ulceration in, 372-374
ultrasound follow-up in, 353-354
ultrasound staging of, 358-359
viewing of, 309
vinorelbine, tamoxifen regimen in, 421
Melanoma antigen gene-2, 86
Melanoma antigen gene-6, 86
Melanoma cell, genetic targeting of, 510
Melimmune-2, 466
Melphalan, 404
isolated hepatic perfusion with, 138-141, 142
in isolated limb perfusion, 401
Menogaril, for mesothelioma, 63
Mesothelial cell, 2
Mesothelioma
asbestos and, 9-10
asbestosis frequency *v*, 8
epithelial, 56, 57
human, and SV40, 10
latency of, 14
malignant, *see* Malignant mesothelioma
malignant pleural, *see* Malignant pleural mesothelioma
multicystic, 2-3
nonoccupational, 20
occupational asbestos exposure and, 19-20
peritoneal, *see* Peritoneal mesothelioma
radiation and, 11

Metastasis, melanoma, 356
Methotrexate
in combination chemotherapy, 66-67
for mesothelioma, 64-65
MF11-30, 465
Microarray
cell, 284
DNA, *see* DNA microarray
tissue, 283
Micrometastasis, in melanoma, 275-276
Microphthalmia transcription factor, 375
Microsatellite instability, 214
in colon cancer, 227
Minigene coding, 499
Misonidazole, external-beam radiation therapy and, 200
Mistletoe
clinical studies of, 590-591
preclinical studies of, 589-590
toxicity of, 592
Mistletoe herbal therapy, 534
Mitolactol, in melanoma, 428
Mitomycin
in combination chemotherapy, 66-67
for mesothelioma, 63
Mitoxantrone, for mesothelioma, 63
Mohs micrographic surgery, 336-337
malignant melanoma therapy and, 337-338
modification of, 338-339
Rush permanent section specimen of, 339
Mole-Analyzer, 310
Molecular diagnosis, future of, in clinical oncology, 262-263
Monitoring, definition of, 287-288
Monochemotherapy, 446
in metastatic melanoma, 413-417, 427
Monoclonal antibody
as assay reagent, 233
mechanism of action of, 472
Most significant irregularity index, 318
Multicystic mesothelioma, 2-3
Multilocular peritoneal inclusion cyst, 2-3

National Cancer Institute
Complementary and alternative medicine research at, 547-550
in complementary and alternative medicine cancer research, 546-547
Physicians Data Query website, 534
National Center for Complementary and Alternative Medicine, 531
cancer therapy research of, 540
comprehensive cancer centers of, 540-541
funding history of, 539
phase II-III randomized controlled trials of, 541
specialized grant centers of, 540-542
Neck, squamous cell carcinoma of, p53 and, 252-253
Neurofibromatosis 2 tumor-supressor gene, 87
Nevus, 313
Nitrogen mustard, 404
Nitrosourea agents, in metastatic melanoma, 415-416
NK cell, in malignant mesothelioma, 83
Northern blot, 232
Nutritional supplements, in prostate cancer, 575-577
NY-ESO-1, 494

Ocular melanoma, isolated hepatic perfusion in, 141-143
Office of Complementary and Alternative Medicine, at National Cancer Institute, 548-549
OK-432, 163-164
Oncogene, 375
Oncolytic virus, 205-206
One A7, 466
Optical coherence tomography, 320-321
Oridonin, 535
Overall irregularity index, 318
Oxaliplatin, 79
in combination chemotherapy, 66-67
Oxford Overview, 219

P6 acupuncture point, 533-534
p53, 203, 205-206, 225
activation of, 249
analysis of, 249
assay for, 215
bladder cancer and, 251
breast cancer and, 251-252
cancer and, 249-250
colon cancer and, 250-251
function of, 246-249
lung cancer and, 252
map of, 248
mutations of, 249-250
predictive significance of, 250
prognostic significance of, 250
prostate cancer and, 252
as screening tool, 253-254
squamous cell carcinoma and, 252-253
structure of, 246
Pab240, 249
Paclitaxel
intraperitoneal, pharmacokinetics of, 57-58
in melanoma, 416, 428
for mesothelioma, 66
in metastatic melanoma, 430-431
Paclitaxel, tamoxifen regimen, in melanoma, 420-421
Palliation
complementary and alternative medicine approaches for, 533
in malignant mesothelioma, 98
Pancreatin, as cancer therapy, 535-536
Papain, in cancer therapy, 536
PC-SPES
clinical efficacy of, 579
clinical studies of, 579-580
preclinical studies of, 577-579
recent developments in, 581-582
toxicity of, 581
PC-SPES herbal mixture, 534
Pemetrexed, in combination chemotherapy, 78-79
Percutaneous alcohol ablation
complications of, 193
response following, 192-193
results of, 193-194
technique for, 192

Peritoneal mesothelioma
aggressive local-regional therapy in, 55-58
CT diagnosis of, 53
cystic type of, 54
definitive diagnosis of, 52-55
demographic data in, 51-52
diagnosis of, 51-52
dry type of, 54, 56
immunostains of, 57
initial signs and symptoms of, 52
morbidity of, 59
mortality of, 59
pathology of, 55, 57
survival of, 59
treatment of, 58-59
wet type of, 53
Photodynamic therapy, in multimodality therapy, 48
Pirarubicin
in combination chemotherapy, 66-67
for mesothelioma, 63
Plasminogen activator inhibitor 1, 217-218, 227
Platelet-derived growth factor, in mesothelioma, 92
Pleural effusion, 3
Pleural plaque, 3
Polychemotherapy
in melanoma, 417-422
for mesothelioma, 66-67
in metastatic melanoma, 431-435, 446
Polymerase chain reaction
differential, 232
reverse-transcriptase, *see* Reverse-transcriptase polymerase chain reaction
Poppy seed oil, 145
Positron emission tomography
in hepatic metastasis evaluation, 111-112
in malignant pleural mesothelioma, 29-30
Practice Outcomes Monitoring and Evaluation System, 549
Predictive factor, 227
c-erbB-2 as, 235-239
definition of, 222-223
p53 as, 250
Predictive marker, clinical trial design for, 227, 228
Premarket approval application, FDA, 295
Progesterone receptor, as marker, 232
Prognosis, definition of, 287
Prognostic factor
c-erbB-2 as, 234-235
clinical trial for, sample size for, 225
definition of, 222-223
p53 as, 250
study design for, 226
Prognostic factor hypothesis, treatment hypothesis and, 227
Program for the Assessment of Clinical Cancer Tests, 214
Prostate cancer
acupuncture in, 577
androgen-dependent, 579-580
androgen-independent, 580
asymptomatic hormone-refractory, treatment of, 290-291
herbal mixture for, 534-535
herbal therapy in, 577-582
hormone-refractory, and prostate-specific antigen, 269-270
Prostate cancer (*Continued*)
lycopene in, 576-577
metastatic, and prostate-specific antigen, 268-269
p53 and, 252
selenium in, 576
soy protein in, 576
vitamin E in, 576
Prostate-specific antigen
as prognostic factor, 223
bouncing, 266
disease-free status and, 265
external-beam radiation therapy and, 266
following radical prostatectomy, 267-268
following radiotherapy, 265
free *v* total, 264-265
hormone-refractory prostate cancer and, 269-270
metastatic disease and, 268-269
response to, 291
rising, 290
Prostatectomy, prostate-specific antigen following, 267-268
Protein array, 284
Protein overexpression, 232
Proteolytic enzyme, 375
PSAdynia, definition of, 291
Pseudonetwork, 314
Pseudopod, 314
Pseudoreticulum, 314
Pyrazoloacridine, 439

QS-21, 466, 497
Quality of life, in malignant mesothelioma, 98
Quick and Simple and Reliable trial, 224

Rabdosia rubscens, 535
Radial streaming, 314
Radiation
in diffuse malignant pleural mesothelioma, 43-45
effects of, on liver, 196-197
external-beam, 47
human mesothelioma and, 11
liver disease induced by, 196-197
Radiobiology, principles of, and cell kill, 519-520
Radioembolization
laboratory findings following, 154
results of, 153-154
selecting patients for, 152-153
side effects of, 155
tumor response to, 154
Radiofrequency ablation
background of, 168-169
imaging following, 173-175
multiprobe array system for, 171
other ablative techniques *v*, 180-181
with other therapies, 179-180
patient selection for, 171-172
results of, 175-179
technique for, 169-171
treatment approaches with, 173
Radioisotope technique, in melanoma, 344-345

Radiosurgery
in brain metastasis, 514, 519
stereotactic, in brain metastasis, 520-521
Radiotherapy
external-beam, *see* External-beam radiation therapy
of liver, 197-198
prostate-specific antigen following, 265
RAGE gene, 480-481
Raltitrexed, in combination chemotherapy, 79
Randomization, double, in clinical trial design, 228-229
Ranpirnase, for mesothelioma, 65
Rappaport classification, 258
Recognition, definition of, 311
Reflectance spectroscopy, 319
Reverse-transcriptase polymerase chain reaction, 215, 275, 348-349
quantitative, 223-224, 283
Revised European-American Lymphoma and World Health Organization classification, 258
RNA interference, 284

S100, 376-377
Safety, FDA definition of, 295
Sample size, in clinical trials, 227
Saponin, 535
Saw palmetto, 534-535
SEER program, 3
Segmentation, definition of, 311
Selected Vegetables and Herb Mix, 535
Selenium, in prostate cancer, 576
Semustine
in melanoma, 428
in metastatic melanoma, 430
Sentinel lymph node
analysis methods of, 274-275
in invasive breast cancer, 277
selective dissection of, 342-343
Sentinel lymph node biopsy
histopathologic workup protocol for, 376
in melanoma, 330-334, 341-342, 375-378
micrometastasis of, clinical significance of, 349
patient selection for, 349-350
technique of, 347-348
Sentinel lymph node specimen, histophathologic analysis of, 348-349
SEREX, 86
Serologic analysis, of recombinant complementary DNA expression libraries, 86
Seven-point checklist, 309
Simian virus 40, 6, 14, 86
human mesothelioma and, 10
pathogenic mechanisms of, 5
Single-strand conformation polymorphism, 215
Skullcap, 534-535
Slow Mohs, 339
Smoking, mesothelioma and, 3-4
Sonography, intraoperative, of liver, 113-114
Southern blot, 232
Soy protein, in prostate cancer, 576
Spectrophotometric image analysis, 319
Squamous cell carcinoma, p53 and, 252-253
ST1-571, in mesothelioma, 91-92
Stomal tumor, gastrointestinal, 225
Streak, 314
Stress, and cancer, 596
Structure fractal dimension, 318
Structureless area, 314
SU5416, 440
in mesothelioma, 91-92
Submesotheliomal cell, 3
Sugarbaker staging system, 43
Suicide gene therapy, 87-88, 203-205
tumor vaccine plus, 89
Suicide gene-based gene therapy, 508
Surveillance, Epidemiology and End Results program, 3

TAB-250, 233
Tamoxifen, 436, 437, 450
high-dose, plus cisplatin, in melanoma, 420
in melanoma, 428
Tamoxifen, cisplatin regimen, in melanoma, 396-397, 420
Tamoxifen, dacarbazine, carboplatin regimen, in melanoma, 421
Tamoxifen, dacarbazine, carmustine, cisplatin regimen, in melanoma, 417-420
Tamoxifen, dacarbazine, cisplatin regimen, in melanoma, 421
Tamoxifen, dacarbazine, fotemustine, cisplatin regimen, in melanoma, 420
Tamoxifen, paclitaxel regimen, in melanoma, 420-421
Tamoxifen, vinorelbine regimen, in melanoma, 421
Tamoxifen therapy
adjuvant, 236
c-erbB-2 and, 236
TaqMan, 283
Taxane(s), c-erbB-2 and, 239
in melanoma, 416
Temozolomide
in brain metastasis, 515
dacarbazine *vs*, in metastatic melanoma, 428-429
in melanoma, 428
in metastatic melanoma, 414-415
Thalidomide, 440
in melanoma, 417
in mesothelioma, 91
Thymidine kinase gene, 203-205
Thymidylate synthase, 215
assay for, 223-224
Tirapazamine, cisplatin regimen, in melanoma, 422
Tissue microarray, 283
TNM classification, of melanoma, 362
TNM International Staging System, for diffuse malignant pleural mesothelioma, 32
Topodermatography, 319-320
Topotecan, for mesothelioma, 66
Traditional Chinese medicine
for breast cancer prevention, 568-569
in breast cancer, 563-568
as neoadjuvant breast cancer therapy, 572
as sole breast cancer therapy, 571-572
Western medicine plus, in breast cancer, 569-571
Traditional Oriental medicine, 533-534
Transcutaneous electrical nerve stimulation, 533

Trastuzumab, 239-240
Tremolite, 4, 22
Trimetrexate, for mesothelioma, 64-65
Trypsin, in cancer therapy, 536
TS106 antibody, 223
Tumor, virtual dissection of, 281
Tumor marker(s)
  anxiety and, 291
  assay standardization for, 218
  assay validation for, 219
  in breast cancer, 213
  central laboratory testing and, 224
  classification of, 294-295
  as clinical cancer test, 211-212
  clinical utility assessment of, 217-218
  clinical utility validation for, 219
  development pathway proposal for, 213-214
  development process for, 223-224
  diagnosis and, 287
  FDA submissions for, 296-297
  FDA-approved, 295
  identification of, 214-215
  monitoring and, 287-288
  prevalence of, 224-225
  processing information about, 291-292
  prognosis and, 287
  prognostic, 231
  reclassification of, 295-296
  rising, 290
  screening and, 286-287
  standardized assay for, 215-217
  study design for, 224-226
Tumor marker clinical trial
  designs of, 226-229
  endpoint selection in, 226
  marker prevalence and, 225
  sample size for, 225
Tumor Marker Utility and Grading System, 219, 222
Tumor Marker Utility Grading Worksheet, 291
Tumor necrosis factor, 404
  in malignant mesothelioma, 85
Tumor necrosis factor-alpha, 138-141, 401
Tumor vaccine, suicide gene therapy plus, 89
Tumor-specific shared antigen, 494
Tumor-suppressor gene
  in mesothelioma, 13-15
  replacement of, 87
  replacing defective, 203

Ulceration, in melanoma, 367
Ultrasonography
  cryotherapy and, 184-185
Ultrasonography (*Continued*)
  intraoperative, 113-114, 184-185
  laparoscopic, 173
  of liver, 113-114
  of radiofrequency ablation, 172
Ultrasound
  anchor wire melanoma metastasis marking guided by, 357-358
  fine-needle aspiration cytology guided by, 357
  in melanoma staging, 358-359
Ultrasound analysis, 320-321
  lymph node B-scan pattern in, 355-356
  in melanoma follow-up, 353-354
Urokinase-type plasminogen activator, 217-218, 227

Vaccine
  anti-Id, 463
  cell-based melanoma, 481-482
  DNA, 486
  immune response following, monitoring of, 499-500
  in melanoma, 383
  mesothelioma, 89-90
  peptide, 482-484, 495, 497-498
  tumor, plus suicide gene therapy, 89
Vaccinia melanoma oncolysate, 482
Vaccinia virus, 485-486, 89
Vascular endothelial growth factor, 91-92
Vassallo index, 355
Vegetables and Herb Mix, 535
Video-assisted thoracic surgery, 41
Vinblastine, 436, 437, 450
  in combination chemotherapy, 66-67
  for mesothelioma, 66
  in polychemotherapy, for metastatic melanoma, 432
Vincristine, for mesothelioma, 66
Vincristine, bleomycin, lomustine, dacarbazine regimen, in melanoma, 422
Vindesine, for mesothelioma, 66
Vindesine, dacarbazine regimen, in melanoma, 421-422
Vinorelbine
  for mesothelioma, 66
  in combination chemotherapy, for mesothelioma, 66-67
Vinorelbine, tamoxifen regimen, in melanoma, 421
Vitamin E, in prostate cancer, 576

Whole brain irradiation, in brain metastasis, 514-515
Working Formulation, 258

ZAP-70, 261, 262
ZD 1839, in mesothelioma, 91-92